Clinical trials: Stage III Skin Cancer
Triple Negative Breast Neoplasms
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).
- Trial name
- IMpassion132 (NCT03371017)
- Testing
- Atezolizumab, Gemcitabine, Capecitabine
- Where
- 124 sites in United States, Argentina and 26 more
- Volunteers
- 595 people
- Sponsor
- Hoffmann-La Roche
Kidney Cancer, Melanoma (Skin)
Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases
RATIONALE: Cryoablation kills cancer cells by freezing them. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Pain
- Trial name
- NCT00540969
- Testing
- cryosurgery, radiation therapy
- Where
- 7 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma
Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
The primary objective of this study is to investigate the effectiveness of intralesional (IL) PV-10 for locoregional treatment of metastatic melanoma.
- Trial name
- NCT00521053
- Testing
- PV-10 (10% rose bengal disodium)
- Where
- 7 sites in United States, Australia
- Volunteers
- 80 people
- Sponsor
- Provectus Pharmaceuticals
B-Cell Neoplasm, Estrogen Receptor Negative
18F-FSPG PET/CT for Cancer Patients on Therapy
The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic…
- Conditions
- B-Cell Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Renal Cell Cancer
- Trial name
- NCT02599194
- Testing
- 18F-FSPG, 18F-FDG
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Andrei Iagaru
Breast Cancer
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
This is a randomized, Phase III, open-label, multicenter study.
- Trial name
- TITAN (NCT00789581)
- Testing
- Doxorubicin, Cyclophosphamide, Ixabepilone (Ixempra)
- Where
- 70 sites in United States, Puerto Rico
- Volunteers
- 614 people
- Sponsor
- SCRI Development Innovations, LLC
Melanoma
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.
- Trial name
- COMBI-v (NCT01597908)
- Testing
- Dabrafenib, Vemurafenib, Trametinib
- Where
- 205 sites in United States, Argentina and 26 more
- Volunteers
- 704 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00693719
- Testing
- Etoposide, Irinotecan hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Arizona
Breast Cancer
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00331630
- Testing
- lapatinib ditosylate, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Breast Cancer
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
RATIONALE: A breath test that measures enzymes may be effective in identifying women in whom tamoxifen may not be effective. PURPOSE: This clinical trial is studying a breath test to see how well it works in women receiving…
- Trial name
- NCT00873366
- Testing
- dextromethorphan hydrobromide, tamoxifen citrate, high performance liquid chromatography
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Mayo Clinic
Breast Cancer
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
To test whether the addition of the COX-2 inhibitor, celecoxib, will decrease the gene expression of CYP19 in breast cancers collected from postmenopausal women that receive neoadjuvant exemestane.
- Trial name
- NCT00201773
- Testing
- Exemestane, Celecoxib, Correlative studies
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00616967
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
This phase II clinical trial studies how well omega-3 fatty acid works in treating patients with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from breast cancer patients receiving omega-3…
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage IA Breast Cancer
- Trial name
- NCT01869764
- Testing
- omega-3 fatty acid, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Wake Forest University Health Sciences
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
This phase II trial studies how well copper Cu64-DOTA-trastuzumab positron emission tomography (PET) works in predicting response to treatment with trastuzumab and pertuzumab before surgery in patients with human epidermal growth…
- Conditions
- HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT02827877
- Testing
- Copper Cu 64-DOTA-Trastuzumab, Laboratory Biomarker Analysis, Pertuzumab
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Melanoma
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
Cancers develop in two different ways. First, cancer cells can become invisible to the immune system by stop having proteins on their surface that are required for the immune system to recognize them.
- Trial name
- NCT03765229
- Testing
- Entinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00118053
- Testing
- herceptin, carboplatin, docetaxel
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Mucosal Melanoma, Recurrent Melanoma
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma.
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Recurrent Uveal Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT01961115
- Testing
- Epacadostat, MELITAC 12.1 Peptide Vaccine
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
The PIPAC nab-pac study is designed to examine the maximal tolerated dose of albumin bound nanoparticle paclitaxel (nab-pac, Abraxane) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a…
- Conditions
- Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB, Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
- Trial name
- PIPAC-nabpac (NCT03304210)
- Testing
- PIPAC with Abraxane
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Ghent
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT01902173
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 16 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)